Cytosorbents’ (CTSO) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the medical research company’s stock. CTSO has been the topic of a number of other reports. HC Wainwright reiterated a “neutral” rating […]
D. Boral Capital reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the medical research company’s stock. CTSO has been the topic of a number of other reports. HC Wainwright reiterated a “neutral” rating […]
